BridgeBio Pharma Return on Tangible Equity 2018-2024 | BBIO

Current and historical return on tangible equity values for BridgeBio Pharma (BBIO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
BridgeBio Pharma Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-06-30 $-0.45B $-1.11B 38.06%
2024-03-31 $-0.54B $-1.06B 42.77%
2023-12-31 $-0.64B $-1.37B 49.37%
2023-09-30 $-0.61B $-1.22B 47.96%
2023-06-30 $-0.57B $-1.38B 45.40%
2023-03-31 $-0.43B $-1.24B 36.06%
2022-12-31 $-0.48B $-1.27B 42.35%
2022-09-30 $-0.49B $-1.16B 46.86%
2022-06-30 $-0.51B $-1.04B 53.42%
2022-03-31 $-0.60B $-1.07B 73.80%
2021-12-31 $-0.56B $-0.91B 88.40%
2021-09-30 $-0.54B $-0.79B 140.33%
2021-06-30 $-0.50B $-0.46B 377.86%
2021-03-31 $-0.52B $-0.39B -803.09%
2020-12-31 $-0.45B $0.11B -163.72%
2020-09-30 $-0.40B $0.22B -109.76%
2020-06-30 $-0.35B $0.33B -78.15%
2020-03-31 $-0.29B $0.45B -80.55%
2019-12-31 $-0.26B $0.47B -104.42%
2019-06-30 $-0.16B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00